Research

CUHK Study Proves Ablative Chemoembolization Doubles the Progression-Free Survival for Liver Cancer Patients

27 March 2018

From left: Prof. Winnie YEO, Professor of the Department of Clinical Oncology; Prof. Simon YU, Chairman of the Department of Imaging and Interventional Radiology; Dr. Kit Fai LEE, Clinical Associate Professor (honorary) of the Department of Surgery, from the Faculty of Medicine at CUHK

From left: Prof. Winnie YEO, from Department of Clinical Oncology; Prof. Simon YU, from Department of Imaging and Interventional Radiology; Dr. Kit Fai LEE, from Department of Surgery, CUHK Medicine

Abstract

A study conducted by a multidisciplinary team of the Faculty established that “Ablative Chemoembolization” (ACE), a new transarterial treatment, could prolong the progression-free survival of liver cancer patients at the intermediate stage by twice the length of time of “conventional transarterial chemoembolization” (cTACE). Results were published in the medical journal Radiology.

Details: http://bit.ly/2U6mxep

Back to Listing page

CUHK Study Shows Behavioural Activation with Mindfulness Lower Major Depression Risk

CUHK Researchers Achieve Breakthrough in the Mechanism of Maintaining Body Iron Homeostasis